Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.

This prospective, single-arm phase II study evaluated neoadjuvant tislelizumab (anti–PD-1) plus SOX (S-1 and oxaliplat...

Continue ReadingThree-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.

Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024).

This publication presents a consensus developed by the Chinese Society of Hepatology on managing liver injury induced by...

Continue ReadingConsensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024).

Efficacy of endoscopic therapy in patients with T1b gastric cancer and construction of a prognostic prediction model: a retrospective cohort study and multicenter validation study.

This study compared long-term survival outcomes among T1b gastric cancer patients treated with endoscopic therapy, gastr...

Continue ReadingEfficacy of endoscopic therapy in patients with T1b gastric cancer and construction of a prognostic prediction model: a retrospective cohort study and multicenter validation study.

Stereotactic body radiotherapy versus laparoscopic liver resection for single hepatocellular carcinoma ≤ 5 cm: a retrospective, multicenter, cohort study.

This retrospective study compared stereotactic body radiotherapy (SBRT) and laparoscopic liver resection (LLR) in 383 pa...

Continue ReadingStereotactic body radiotherapy versus laparoscopic liver resection for single hepatocellular carcinoma ≤ 5 cm: a retrospective, multicenter, cohort study.